Vijay Ramakrishnan

923 total citations
26 papers, 732 citations indexed

About

Vijay Ramakrishnan is a scholar working on Hematology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Vijay Ramakrishnan has authored 26 papers receiving a total of 732 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 18 papers in Molecular Biology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Vijay Ramakrishnan's work include Multiple Myeloma Research and Treatments (18 papers), Cancer Mechanisms and Therapy (6 papers) and Protein Degradation and Inhibitors (6 papers). Vijay Ramakrishnan is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Cancer Mechanisms and Therapy (6 papers) and Protein Degradation and Inhibitors (6 papers). Vijay Ramakrishnan collaborates with scholars based in United States, China and Czechia. Vijay Ramakrishnan's co-authors include Shaji Kumar, S. Vincent Rajkumar, Teresa K. Kimlinger, Linda Wellik, Michael Timm, Jessica Haug, Janine Haug, Prashant Kapoor, Nidhi Tandon and John R. Sauer and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Vijay Ramakrishnan

25 papers receiving 722 citations

Peers

Countries citing papers authored by Vijay Ramakrishnan

Since Specialization

Citations

This map shows the geographic impact of Vijay Ramakrishnan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vijay Ramakrishnan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vijay Ramakrishnan more than expected).

Fields of papers citing papers by Vijay Ramakrishnan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vijay Ramakrishnan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vijay Ramakrishnan. The network helps show where Vijay Ramakrishnan may publish in the future.

Co-authorship network of co-authors of Vijay Ramakrishnan

This figure shows the co-authorship network connecting the top 25 collaborators of Vijay Ramakrishnan. A scholar is included among the top collaborators of Vijay Ramakrishnan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vijay Ramakrishnan. Vijay Ramakrishnan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma 2020 ·Blood Cancer Journal ·Amit Mitra, Harish Kumar, Vijay Ramakrishnan, Li Chen, Linda B. Baughn, Shaji Kumar, S. Vincent Rajkumar, Brian G. Van Ness	13
2	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma 2019 ·Haematologica ·Vijay Ramakrishnan, Kevin C. Miller, (unknown), Teresa K. Kimlinger, Jessica Haug, Sanjay Kumar, Wilson I. Gonsalves, S. Vincent Rajkumar, Shaji Kumar	27
3	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies 2018 ·JCI Insight ·Wilson I. Gonsalves, Vijay Ramakrishnan, Taro Hitosugi, (unknown), Dragan Jevremović, Tumpa Dutta, Dhananjay Sakrikar, (unknown), Linda Wellik, Shaji Kumar, K. Sreekumaran Nair	44
4	PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise 2018 ·Leukemia & lymphoma ·Vijay Ramakrishnan, Shaji Kumar	60
5	Clinical use and applications of histone deacetylase inhibitors in multiple myeloma 2016 ·Clinical Pharmacology Advances and Applications ·Shaji Kumar, Nidhi Tandon, Vijay Ramakrishnan	46
6	Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma 2016 ·The Cancer Journal ·Vijay Ramakrishnan, Shaji Kumar	4
7	Signaling Pathways and Emerging Therapies in Multiple Myeloma 2016 ·Current Hematologic Malignancy Reports ·Vijay Ramakrishnan, Anita D’Souza	17
8	Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma 2016 ·Oncotarget ·Vijay Ramakrishnan, Marcus V. Gomez, Vivek Prasad, Teresa K. Kimlinger, (unknown), (unknown), Jessica Haug, Lintao Bi, S. Vincent Rajkumar, Shaji Kumar	20
9	Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma 2014 ·Leukemia ·Vijay Ramakrishnan, (unknown), Teresa K. Kimlinger, Janine Haug, S. Vincent Rajkumar, Shaji Kumar	43
10	Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001 2014 ·Leukemia Research ·Vijay Ramakrishnan, Teresa K. Kimlinger, Michael Timm, Jessica Haug, S. Vincent Rajkumar, Shaji Kumar	13
11	Bortezomib Combination Therapy in Multiple Myeloma 2012 ·Seminars in Hematology ·Prashant Kapoor, Vijay Ramakrishnan, S. Vincent Rajkumar	60
12	Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway 2012 ·PLoS ONE ·Vijay Ramakrishnan, Teresa K. Kimlinger, Jessica Haug, (unknown), Linda Wellik, (unknown), S. Vincent Rajkumar, Shaji Kumar	52
13	Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin 2011 ·American Journal of Hematology ·Vijay Ramakrishnan, Michael Timm, Jessica Haug, Teresa K. Kimlinger, (unknown), Linda Wellik, Thomas E. Witzig, S. Vincent Rajkumar, Alex A. Adjei, Shaji Kumar	29
14	MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma 2011 ·Leukemia ·Vijay Ramakrishnan, Stephen M. Ansell, Janine Haug, D M Grote, Teresa K. Kimlinger, Mary Stenson, Michael Timm, (unknown), (unknown), S. Vincent Rajkumar, Shaji Kumar	60
15	TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells 2010 ·American Journal of Hematology ·Vijay Ramakrishnan, Teresa K. Kimlinger, Jessica Haug, Michael Timm, Linda Wellik, (unknown), Animesh Pardanani, Ayalew Tefferi, S. Vincent Rajkumar, Shaji Kumar	49
16	Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs 2009 ·Oncogene ·Vijay Ramakrishnan, Michael Timm, Janine Haug, Teresa K. Kimlinger, Linda Wellik, Thomas E. Witzig, S. Vincent Rajkumar, Alex A. Adjei, Shaji Kumar	73
17	Microarray analysis of gene expression changes in feeding female and male lone star ticks, Amblyomma americanum (L) 2009 ·Archives of Insect Biochemistry and Physiology ·Majd Aljamali, Vijay Ramakrishnan, Hua Weng, J. S. Tucker, John R. Sauer, Richard C. Essenberg	27
18	Structures of the Iron-Sulfur Flavoproteins fromMethanosarcina thermophilaandArchaeoglobus fulgidus 2005 ·Journal of Bacteriology ·Susana L. A. Andrade, (unknown), Catherine L. Drennan, Vijay Ramakrishnan, Douglas C. Rees, James G. Ferry, Oliver Einsle	12
19	Amblyomma americanum salivary gland homolog of nSec1 is essential for saliva protein secretion 2004 ·Biochemical and Biophysical Research Communications ·Shahid Karim, Vijay Ramakrishnan, J. S. Tucker, Richard C. Essenberg, John R. Sauer	22
20	Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers. 1990 ·Journal of Biological Chemistry ·Vijay Ramakrishnan, Dominick Sinicropi, Ruhee Dere, Walter C. Darbonne, Kathleen B. Bechtol, Joffre Baker	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact